Search research articles
Contact Us
Filters
Showing results (531-540 of 551) with videos related to
Page
of 56
Sort By:
The Journal of Infectious Diseases
|
June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zoe Moodie, One Dintwe, Sheetal Sawant, et al.
Cell
|
November 2, 2025
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Wilton B Williams, S Munir Alam, Gilad Ofek, et al.
Nature Communications
|
April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Cell
|
May 18, 2024
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Wilton B Williams, S Munir Alam, Gilad Ofek, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Science (New York, N.Y.)
|
August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies
Wilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.
Science Translational Medicine
|
April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
David Benkeser, David C Montefiori, Adrian B McDermott, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials
Carolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, et al.
Nature Communications
|
March 12, 2024
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Craig A Magaret, Li Li, Allan C deCamp, et al.
Page
of 56
Search research articles
Search
Showing results (531-540 of 551) with videos related to
Sort By:
Page
of 56
The Journal of Infectious Diseases
|
June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zoe Moodie, One Dintwe, Sheetal Sawant, et al.
Cell
|
November 2, 2025
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Wilton B Williams, S Munir Alam, Gilad Ofek, et al.
Nature Communications
|
April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Cell
|
May 18, 2024
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Wilton B Williams, S Munir Alam, Gilad Ofek, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Science (New York, N.Y.)
|
August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies
Wilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.
Science Translational Medicine
|
April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
David Benkeser, David C Montefiori, Adrian B McDermott, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials
Carolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, et al.
Nature Communications
|
March 12, 2024
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Craig A Magaret, Li Li, Allan C deCamp, et al.
Page
of 56